Table 1

Baseline characteristics and scores on ASAS core set measures of the study patients (mean (SD))

Total study group (n=162)
*Median (interquartile range).
ASAS, ASsessments in Ankylosing Spondylitis; HLA, human leucocyte antigen; IBD, inflammatory bowel disease; BASFI, Bath Ankylosing Spondylitis Functional Index; VAS, visual analogue scale; ESR, erythrocyte sedimentation rate; CRP, C reactive protein.
Age (years)44.9 (12.3)
Duration of complaints (years)21.6 (12.0)
Time since diagnosis (years)11.4 (9.2)
HLA-B27 (present/absent/no data)105/18/39
History of IBD (present/absent)17/145
History of uveitis (present/absent)62/100
History of psoriasis (present/absent)10/152
BASFI3.7 (2.4)
VAS pain of the spine (cm)3.5 (2.3)
Night pain (4 point Likert)1.2 (0.8)
Chest expansion (cm)4.2 (1.9)
10 cm Schober (cm)2.6 (1.4)
Occiput to wall distance (cm)*2.7 (0.0–7.5)
VAS patient global (cm)3.4 (2.7)
Arthritis as measured by swollen joints
ESR (mm/1st h)*9 (4–17)
CRP (mg/l)*7 (6–16)
VAS doctor for disease activity (cm)1.8 (1.8)
VAS doctor for disease activity* (cm)1.0 (0.5–2.6)
VAS patient for disease activity (cm)3.5 (2.6)
VAS patient for disease activity* (cm)3.0 (1.1–5.2)
Duration of morning stiffness (min)37 (29)